Stock Library / MDGL

MDGL Healthcare Latest YouTube: Q1 2026 Published 2026-05-10

Madrigal Pharmaceuticals, Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

MDGL Stock: EPS Beats, Revenue Misses — Q1 2026

Published 2026-05-10

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q1 2026

2026-05-10

Podcast available

Yes

Current price

$516.74

-3.25 (-0.63%)

Trailing / Forward P/E

—

Forward: 53.69x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

71.2%

Earnings: —

Margins

-15.5% op

Gross: 91.5% · Net: -25.3%

Balance sheet

3.21x current

Debt / Equity: 66.4

52-week range / Beta

$393.61 - $615.00

Beta: -1.00

Analyst target

$678.06

Upside: 31.2%

Cash / shareholder return

-0.67% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: 22.79x

Return on equity: -53.3%

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Price chart

Market context for MDGL

Competitive view

MDGL vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Madrigal Pharmaceuticals, Inc. latest YouTube video thumbnail

Madrigal Pharmaceuticals, Inc.

MDGL

YouTube Podbean

Latest video

Q1 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

MDGL

$11.94B

Madrigal Pharmaceuticals, Inc.

ISRG

$135.72B

Intuitive Surgical

JNJ

$651.25B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

MDGL

—

Madrigal Pharmaceuticals, Inc.

ISRG

43.5x

Intuitive Surgical

JNJ

31.4x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

MDGL

53.7x

Madrigal Pharmaceuticals, Inc.

ISRG

31.4x

Intuitive Surgical

JNJ

22.0x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

MDGL

71.2%

Madrigal Pharmaceuticals, Inc.

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

MDGL

—

Madrigal Pharmaceuticals, Inc.

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

MDGL

-15.5%

Madrigal Pharmaceuticals, Inc.

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

MDGL

91.5%

Madrigal Pharmaceuticals, Inc.

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

MDGL

-25.3%

Madrigal Pharmaceuticals, Inc.

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

MDGL

-53.3%

Madrigal Pharmaceuticals, Inc.

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

MDGL

-0.7%

Madrigal Pharmaceuticals, Inc.

ISRG

1.9%

Intuitive Surgical

JNJ

2.6%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

MDGL

66.40x

Madrigal Pharmaceuticals, Inc.

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

MDGL

3.21x

Madrigal Pharmaceuticals, Inc.

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

MDGL

-1.00

Madrigal Pharmaceuticals, Inc.

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

MDGL

—

Madrigal Pharmaceuticals, Inc.

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

MDGL

31.2%

Madrigal Pharmaceuticals, Inc.

ISRG

26.2%

Intuitive Surgical

JNJ

0.8%

Johnson & Johnson

Episode timeline

Episode archive for MDGL

Each row is one earnings episode with every verified platform link available.

Q1 2026

Episode live

2026-05-10

Published youtube podcast complete

MDGL Stock: EPS Beats, Revenue Misses — Q1 2026

Quarterly earnings-analysis entry for Madrigal Pharmaceuticals, Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music